Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P. Schlaich, Thomas Guldager Lauridsen, George L. Bakris et al.|The Lancet|2022Cited by 223
AHEAD score — Long-term risk classification in acute heart failureJindřich Špinar, Jiří Pařenica, Jiří Jarkovský et al.|International Journal of Cardiology|2015Cited by 94